Other languages BeiGene, Ltd.

Equities

BGNE

US07725L1026

Real-time Estimate Cboe BZX Other stock markets 10:19:48 2024-04-26 am EDT			5-day change	1st Jan Change
153.2 ^USD	+3.12%		+17.43%	-15.67%

Apr. 23	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Apr. 23	BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	Apr. 25
BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024	Apr. 25
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	Apr. 23
BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules	Apr. 23
Sector Update: Health Care Stocks Rise in Afternoon Trading	Apr. 23
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	Apr. 23
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	Apr. 10
Beigene Shrinks Loss by 56% in 2023	Mar. 29
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	Mar. 22
BeiGene, Ltd. Announces Executive Changes	Mar. 20
BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapie	Mar. 15
BeiGene recibe la aprobación de la FDA para TEVIMBRA ® para el tratamiento del carcinoma esofágico de células escamosas avanzado o metastásico luego de una quimioterapia previa	Mar. 15
Beigene's Esophageal Cancer Drug Gets US FDA Nod	Mar. 15
BeiGene erhält FDA-Zulassung für TEVIMBRA ® zur Behandlung des fortgeschrittenen oder metastasierten Plattenepithelkarzinoms der Speiseröhre nach vorheriger Chemotherapie	Mar. 15
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing	Mar. 14
BeiGene Gets FDA Approval for Esophageal Cancer Treatment	Mar. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BeiGene, Ltd.

Equities

BGNE

US07725L1026

Other languages

Filters